Cibc World Markets Corp Takes $666,000 Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Cibc World Markets Corp purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYFree Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 3,482 shares of the biopharmaceutical company’s stock, valued at approximately $666,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Public Employees Retirement Association of Colorado increased its stake in shares of Alnylam Pharmaceuticals by 107.8% in the 4th quarter. Public Employees Retirement Association of Colorado now owns 14,397 shares of the biopharmaceutical company’s stock valued at $2,756,000 after purchasing an additional 7,468 shares during the last quarter. Capital Research Global Investors increased its stake in shares of Alnylam Pharmaceuticals by 5.3% in the 4th quarter. Capital Research Global Investors now owns 2,930,079 shares of the biopharmaceutical company’s stock valued at $560,880,000 after purchasing an additional 146,236 shares during the last quarter. Capital International Sarl increased its stake in shares of Alnylam Pharmaceuticals by 0.5% in the 4th quarter. Capital International Sarl now owns 87,357 shares of the biopharmaceutical company’s stock valued at $16,721,000 after purchasing an additional 435 shares during the last quarter. Capital International Investors increased its stake in shares of Alnylam Pharmaceuticals by 15.8% in the 4th quarter. Capital International Investors now owns 3,586,657 shares of the biopharmaceutical company’s stock valued at $686,641,000 after purchasing an additional 488,814 shares during the last quarter. Finally, First Trust Advisors LP grew its position in Alnylam Pharmaceuticals by 31.4% during the 4th quarter. First Trust Advisors LP now owns 306,693 shares of the biopharmaceutical company’s stock worth $58,704,000 after acquiring an additional 73,203 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of Alnylam Pharmaceuticals stock opened at $153.47 on Tuesday. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $218.88. The firm has a market capitalization of $19.41 billion, a price-to-earnings ratio of -57.06 and a beta of 0.30. The business has a 50-day simple moving average of $149.44 and a 200 day simple moving average of $162.90.

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Free Report) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.23. The firm had revenue of $494.33 million during the quarter, compared to the consensus estimate of $428.01 million. During the same period in the previous year, the firm earned ($1.40) earnings per share. The business’s quarterly revenue was up 54.8% on a year-over-year basis. On average, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -3.77 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ALNY. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, April 8th. Citigroup reduced their price objective on Alnylam Pharmaceuticals from $237.00 to $227.00 and set a “buy” rating on the stock in a research report on Friday, February 16th. Royal Bank of Canada restated an “outperform” rating and set a $235.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Tuesday, February 20th. Cantor Fitzgerald restated a “neutral” rating and set a $165.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Tuesday, February 20th. Finally, The Goldman Sachs Group lowered Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $230.00 to $173.00 in a research report on Friday, February 16th. Seven research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $216.19.

Read Our Latest Research Report on Alnylam Pharmaceuticals

Insider Activity at Alnylam Pharmaceuticals

In related news, Director Amy W. Schulman sold 21,700 shares of the business’s stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $148.60, for a total value of $3,224,620.00. Following the completion of the sale, the director now directly owns 8,436 shares of the company’s stock, valued at approximately $1,253,589.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.50% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Company Profile

(Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Featured Articles

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYFree Report).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.